메뉴 건너뛰기




Volumn 1, Issue 7, 2009, Pages 1193-1200

Metabolites in safety testing

Author keywords

[No Author keywords available]

Indexed keywords

DRUG; PHARMACOLOGICAL BIOMARKER;

EID: 77957116776     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.09.98     Document Type: Review
Times cited : (51)

References (34)
  • 1
    • 61649102842 scopus 로고    scopus 로고
    • Simultaneous quantification of losartan and active metabolite in human plasma by liquid chromatography-tandem mass spectrometry using irbesartan as internal standard
    • Prasaja B, Sasongko L, Harahap Y, Hardiyanti, Lusthom W, Grigg M. Simultaneous quantification of losartan and active metabolite in human plasma by liquid chromatography-tandem mass spectrometry using irbesartan as internal standard. J. Pharm. Biomed. Anal. 49(3), 862-867 (2009).
    • (2009) J. Pharm. Biomed. Anal. , vol.49 , Issue.3 , pp. 862-867
    • Prasaja, B.1    Sasongko, L.2    Harahap, Y.3    Hardiyanti4    Lusthom, W.5    Grigg, M.6
  • 2
    • 67649379367 scopus 로고    scopus 로고
    • Serotonergic drugs and valvular heart disease
    • Rothman RB, Baumann MH. Serotonergic drugs and valvular heart disease. Expert Opin. Drug Saf. 8(3), 317-329 (2009).
    • (2009) Expert Opin. Drug Saf. , vol.8 , Issue.3 , pp. 317-329
    • Rothman, R.B.1    Baumann, M.H.2
  • 4
    • 0033012622 scopus 로고    scopus 로고
    • Quantification in patient urine samples of felbamate and three metabolites: Acid carbamate and two mercapturic acids
    • Thompson CD, Barthen MT, Hopper DW et al. Quantification in patient urine samples of felbamate and three metabolites: acid carbamate and two mercapturic acids. Epilepsia 40, 769-776 (1999).
    • (1999) Epilepsia , vol.40 , pp. 769-776
    • Thompson, C.D.1    Barthen, M.T.2    Hopper, D.W.3
  • 5
    • 33846424676 scopus 로고    scopus 로고
    • Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: A review
    • Masubuchi Y. Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review. Drug Metab. Pharmacokinet. 21(5), 347-356 (2006).
    • (2006) Drug Metab. Pharmacokinet. , vol.21 , Issue.5 , pp. 347-356
    • Masubuchi, Y.1
  • 6
    • 66449102106 scopus 로고    scopus 로고
    • Studies on the chemical reactivity of diclofenax acyl glucuronide with glutathione: Identification of diclofenac-S-acyl-glutathione in rat bile
    • Grillo MP, Knutson CG, Sanders PE, Waldon DJ, Hua F, Ware JA. Studies on the chemical reactivity of diclofenax acyl glucuronide with glutathione: identification of diclofenac-S-acyl-glutathione in rat bile. Drug Metab. Dispos. 37(5), 1073-1082 (2009).
    • (2009) Drug Metab. Dispos. , vol.37 , Issue.5 , pp. 1073-1082
    • Grillo, M.P.1    Knutson, C.G.2    Sanders, P.E.3    Waldon, D.J.4    Hua, F.5    Ware, J.A.6
  • 7
    • 33845734598 scopus 로고    scopus 로고
    • A regulatory perspective on issues and approaches in characterizing human metabolites
    • Davis-Bruno KL, Atrakchi A. A regulatory perspective on issues and approaches in characterizing human metabolites. Chem. Res. Toxicol. 19, 151-1563 (2006).
    • (2006) Chem. Res. Toxicol. , vol.19 , pp. 151-1563
    • Davis-Bruno, K.L.1    Atrakchi, A.2
  • 10
    • 0020409221 scopus 로고
    • Determination of formaldehyde in biological tissues by gas chromatography/mass spectrometry
    • Heck HD, White EL, Casanova-Schmitz M. Determination of formaldehyde in biological tissues by gas chromatography/mass spectrometry. Biomed. Mass Spectrom. 9, 347-353 (1982).
    • (1982) Biomed. Mass Spectrom. , vol.9 , pp. 347-353
    • Heck, H.D.1    White, E.L.2    Casanova-Schmitz, M.3
  • 11
    • 62249100639 scopus 로고    scopus 로고
    • Safety assessment of drug metabolites: Implications of regulatory guidance and potential application of genetically engineered mouse models that express human P450s
    • Powley MW, Frederick CB, Sistare FD, DeGeorge JJ. Safety assessment of drug metabolites: implications of regulatory guidance and potential application of genetically engineered mouse models that express human P450s. Chem. Res. Toxicol. 22, 257-262 (2009).
    • (2009) Chem. Res. Toxicol. , vol.22 , pp. 257-262
    • Powley, M.W.1    Frederick, C.B.2    Sistare, F.D.3    Degeorge, J.J.4
  • 12
    • 33751249069 scopus 로고    scopus 로고
    • Complicating factors in safety testing of drug metabolites: Kinetic differences between generated and preformed metabolites
    • Preuksaritanont T, Lin JH, Baille TA. Complicating factors in safety testing of drug metabolites: kinetic differences between generated and preformed metabolites. Toxicol. Appl. Pharmacol. 217, 143-152 (2006).
    • (2006) Toxicol. Appl. Pharmacol. , vol.217 , pp. 143-152
    • Preuksaritanont, T.1    Lin, J.H.2    Baille, T.A.3
  • 13
    • 59649103035 scopus 로고    scopus 로고
    • Safety testing of metabolites: Expectations and outcomes
    • Pang SK. Safety testing of metabolites: expectations and outcomes. Chem. Biol. Interact. 179, 45-59 (2009).
    • (2009) Chem. Biol. Interact. , vol.179 , pp. 45-59
    • Pang, S.K.1
  • 14
    • 0018121698 scopus 로고
    • Kinetics of metabolite formation and elimination in the perfused rat liver preparation: Differences between elimination of preformed acetaminophen and acetaminophen formed from phenacetin
    • Pang KS, Gillette JR. Kinetics of metabolite formation and elimination in the perfused rat liver preparation: differences between elimination of preformed acetaminophen and acetaminophen formed from phenacetin. J. Pharmacol. Exp. Ther. 207, 178-194 (1978).
    • (1978) J. Pharmacol. Exp. Ther. , vol.207 , pp. 178-194
    • Pang, K.S.1    Gillette, J.R.2
  • 15
    • 24944563781 scopus 로고    scopus 로고
    • Seeing through the MIST: Abundance versus percentage. Commentary on metabolites in safety testing
    • Smith DA, Obach RS. Seeing through the MIST: abundance versus percentage. Commentary on metabolites in safety testing. Drug Metab. Dispos. 33(10), 1409-1417 (2005).
    • (2005) Drug Metab. Dispos. , vol.33 , Issue.10 , pp. 1409-1417
    • Smith, D.A.1    Obach, R.S.2
  • 16
    • 33845748169 scopus 로고    scopus 로고
    • Metabolites and safety: What are the concerns, and how should we address them?
    • Smith DA, Obach RS. Metabolites and safety: what are the concerns, and how should we address them? Chem. Res. Toxicol. 19, 1570-1579 (2006).
    • (2006) Chem. Res. Toxicol. , vol.19 , pp. 1570-1579
    • Smith, D.A.1    Obach, R.S.2
  • 18
    • 34447556889 scopus 로고    scopus 로고
    • Development of safety qualification thresholds and their use in orally inhaled and nasal drug product evaluation
    • Ball D, Blanchard J, Jacobson-Kram D. Development of safety qualification thresholds and their use in orally inhaled and nasal drug product evaluation. Tox. Sci. 97(2), 226-236 (2007).
    • (2007) Tox. Sci. , vol.97 , Issue.2 , pp. 226-236
    • Ball, D.1    Blanchard, J.2    Jacobson-Kram, D.3
  • 19
    • 0008934176 scopus 로고
    • Effects of gastrointestinal disease on drug absorption
    • Benet LZ, Massoud N, Gambertoglio JG (Eds). Raven Press, NY, USA
    • Welling PG. Effects of gastrointestinal disease on drug absorption. In:Pharmacodynamic Basis for Drug Treatment . Benet LZ, Massoud N, Gambertoglio JG (Eds). Raven Press, NY, USA, 29-47 (1984).
    • (1984) Pharmacodynamic Basis for Drug Treatment , pp. 29-47
    • Welling, P.G.1
  • 20
    • 28944450056 scopus 로고    scopus 로고
    • Review article: Similarities and differences among delayedrelease proton pump inhibitor formulations
    • Horn JR, Howden CW. Review article: similarities and differences among delayedrelease proton pump inhibitor formulations. Aliment. Pharmacol. Ther. 22(Suppl. 3), 20-24 (2005).
    • (2005) Aliment. Pharmacol. Ther. , vol.22 , Issue.SUPPL. 3 , pp. 20-24
    • Horn, J.R.1    Howden, C.W.2
  • 21
    • 24044546760 scopus 로고    scopus 로고
    • Metabonomic identification of two distinct phenotypes in Sprague-Dawley (Crl:CD[SD]) Rats
    • Robosky LC, Wells DF, Egnash LA, Manning ML, Reily MD, Robertson DG. Metabonomic identification of two distinct phenotypes in Sprague-Dawley (Crl:CD[SD]) Rats. Tox. Sci. 87(1), 277-284 (2005).
    • (2005) Tox. Sci. , vol.87 , Issue.1 , pp. 277-284
    • Robosky, L.C.1    Wells, D.F.2    Egnash, L.A.3    Manning, M.L.4    Reily, M.D.5    Robertson, D.G.6
  • 22
    • 33645805875 scopus 로고    scopus 로고
    • Communication regarding metabonomic identification of two distinct phenotypes in Sprague-Dawley (Crl:CD[SD]) Rats
    • Robosky LC, Wells DF, Egnash LA, Manning ML, Reily MD, Robertson DG. Communication regarding metabonomic identification of two distinct phenotypes in Sprague-Dawley (Crl:CD[SD]) Rats. Tox. Sci. 91(1), 309 (2006).
    • (2006) Tox. Sci. , vol.91 , Issue.1 , pp. 309
    • Robosky, L.C.1    Wells, D.F.2    Egnash, L.A.3    Manning, M.L.4    Reily, M.D.5    Robertson, D.G.6
  • 23
    • 67650595188 scopus 로고    scopus 로고
    • The role of gut microbiota in drug response
    • Wilson ID, Nicholson JK. The role of gut microbiota in drug response. Curr. Pharm. Des. 15(13), 1519-1523 (2009).
    • (2009) Curr. Pharm. Des. , vol.15 , Issue.13 , pp. 1519-1523
    • Wilson, I.D.1    Nicholson, J.K.2
  • 24
    • 0032589627 scopus 로고    scopus 로고
    • Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: Species differences in the metabolism of efavirenz
    • Mutlib AE, Chen H, Nemeth GA et al. Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz. Drug Metab. Dispos. 27, 1319-1333 (1999).
    • (1999) Drug Metab. Dispos. , vol.27 , pp. 1319-1333
    • Mutlib, A.E.1    Chen, H.2    Nemeth, G.A.3
  • 25
    • 84906677767 scopus 로고    scopus 로고
    • Guidance for industry S1C(R2) dose selection for carcinogenicity studies
    • Guidance for industry (2008) S1C(R2) dose selection for carcinogenicity studies www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/ guidances/ucm074919.pdf
    • (2008)
  • 26
    • 84906668842 scopus 로고    scopus 로고
    • Draft guidance for industry on safety testing of drug metabolites
    • Draft guidance for industry on safety testing of drug metabolites, Federal Register, 70(107), 32839 (2005) http://0-edocket.access.gpo.gov.library. colby. edu/2005/pdf/05-11205.pdf
    • (2005) Federal Register , vol.70 , Issue.107 , pp. 32839
  • 28
    • 0004592386 scopus 로고    scopus 로고
    • US Environmental Protection Agency. OPPTS 870.7485. Metabolism and pharmacokinetics
    • US Environmental Protection Agency (1998). Health effects test guidelines. OPPTS 870.7485. Metabolism and pharmacokinetics www.epa.gov/ opptsfrs/publications/oppts-harmonized/870-health-effects-test-guidelines/ series/870-7485.pdf
    • (1998) Health Effects Test Guidelines
  • 29
    • 84906711200 scopus 로고    scopus 로고
    • Guidance for Industry on Safety Testing of Drug Metabolites
    • Guidance for Industry on Safety Testing of Drug Metabolites (2008) www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ ucm079266.pdf
    • (2008)
  • 30
    • 84906711199 scopus 로고
    • NTP TR 289, Toxicology and carcinogenesis studies of benzene (CAS No. 71-43-42) in F344/N rats and B6C3F1 mice
    • NTP TR 289. Toxicology and carcinogenesis studies of benzene (CAS No. 71-43-42) in F344/N rats and B6C3F1 mice (1986) http://ntp.niehs.nih.gov/ntp/ htdocs/LT-rpts/tr289.pdf
    • (1986)
  • 32
    • 84906694356 scopus 로고    scopus 로고
    • Guideline on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals (step 5 finalized ICH guideline)
    • Guideline on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals (step 5 finalized ICH guideline) www.ich.org/lob/media/media5544.pdf
  • 33
    • 84906711196 scopus 로고
    • Guideline for industry toxicokinetics: the assessment of systemic exposure in toxicity studies (ICH 3A) March
    • Guideline for industry toxicokinetics: the assessment of systemic exposure in toxicity studies (ICH 3A, March 1995) www.fda.gov/downloads/drugs/ guidancecomplianceregulatoryinformation/guidances/ucm074937.pdf
    • (1995)
  • 34
    • 84906711197 scopus 로고    scopus 로고
    • Guidance for industry genotoxic and carcinogenic impurities in drug substances and products: recommended approaches (draft guidance December)
    • Guidance for industry genotoxic and carcinogenic impurities in drug substances and products: recommended approaches (draft guidance, December 2008) www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ ucm079235.pdf
    • (2008)


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.